Urol. praxi, 2012; 13(6): 264-266

Intravesical instillation of propiverine in the treatment of neurogenic bladder dysfunction

MUDr.Zdeněk Dítě, FEAPU, doc.MUDr.Radim Kočvara, CSc., FEAPU
Urologická klinika 1. LF UK a VFN, Praha

Pediatric neuropathic bladder dysfunction can cause not only urinary incontinence, but irreversible renal damage as well. Majority of

patiens suffer from a congenital neural tube defect. Many affected children can be successfully treated with clean intermittent catheterisation

and anticholinergic medication. Patients frequently experience severe side effects or insufficient suppression of detrusor

overactivity. Intravesical instillation of propiverine hydrochloride or oxybutynin chloride offer an effective alternative. We review our

experience with administration, safety and efficacy of intravesical propiverine.

Keywords: dysfunction, catheterisation, intravesical instillation, anticholergics

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dítě Z, Kočvara R. Intravesical instillation of propiverine in the treatment of neurogenic bladder dysfunction. Urol. praxi. 2012;13(6):264-266.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hanuš T. Intermitentní katetrizace močového měchýře. ČLČ 1983; 122: 1135-1137.
    2. Madersbacher H, Halaska M, Voigt R, et al. A placebo-controlled multicenter study comparing the tolerability and efficacy of propiverine and oxybutynin in patiens with urgency ang urge inkontinence. BJU Int 1999; 84: 645-665. Go to original source...
    3. Gupta SK, Sathyan G, Lindemulder EA, et al. Quantitative characterisation of therapeutic index: application of mixed index modelling to evaluate oxybutynin dose-efficacy and dose-side effect relationships. Clin. Pharmacol. Ther. 1999; 65: 672-678. Go to original source... Go to PubMed...
    4. Ferrara P, D'Aleo CM, Tarquini E, Salvatore S, Salvaggio E. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida. BJU Int. 2001; 87: 674-678. Go to original source... Go to PubMed...
    5. Madersbacher H, Jilg G. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. Paraplegia 1991; 29: 84-90. Go to original source... Go to PubMed...
    6. Lazarus J. Intravesical oxybutynin in the pediatric neurogenic bladder. Nat Rev Urol. 2009; 6: 671-674. Go to original source... Go to PubMed...
    7. Guerra LA, Moher D, Sampson M, Barrowman N, Pike J, Leonard M. Intravesical oxybutynin for children with poorly compliant neurogenic bladder: a systematic review. J Urol. 2008; 180: 1091-1097. Go to original source... Go to PubMed...
    8. Haferkamp A, Hohenfellner M. Intravesical treatment of overactive bladder syndrome. Urologe A. 2006; 45: 1283-1288. Go to original source... Go to PubMed...
    9. Saito M, Watanabe T, Tabuchi F, Otsubo K, Satoh K, Miyagawa I. Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol. 2004; 11: 592-596. Go to original source... Go to PubMed...
    10. Amark P, Bussman G, Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children. Eur Urol. 1998; 34: 148-153. Go to original source... Go to PubMed...
    11. Prasad KV, Vaidyanathan S. Intravesical oxybutynin chloride and clean intermittent catheterisation in patients with neurogenic vesical dysfunction and decreased bladder capacity. Br J Urol. 1993; 72: 19-22. Go to original source... Go to PubMed...
    12. Buyse G, Verpoorten C, Vereecken R, Casaer P. Treatment of neurogenic bladder dysfunction in infants and children with neurospinal dysraphism with clean intermittent (self) catheterisation and optimized intravesical oxybutynin hydrochloride therapy. Eur J Pediatr Surg. 1995; 5(Suppl 1): 31-34. Go to original source... Go to PubMed...
    13. Weese DL, Roskamp DA, Leach GE, Zimmern PE. Intravesical oxybutynin chloride: experience with 42 patients. Urology. 1993; 42: 527-530. Go to original source... Go to PubMed...
    14. Massad CA, Kogan BA, Trigo-Rocha FE. The pharmacokinetics of intravesical and oral oxybutynin chloride. J. Urol. 1992; 148: 595-597. Go to original source... Go to PubMed...
    15. George J, Tharion G, Richar J, Macaden AS, Thomas R, Bhattacharji S. The effectiveness of intravesical oxybutynin, propantheline, and capsaicin in the management of neuropathic bladder following spinal cord injury. Scientific Journal. 2007; 7: 1683-1690. Go to original source... Go to PubMed...
    16. Palmer LS, Zebold K, Firlit CF, Kaplan WE. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol. 1997; 157: 638-640. Go to original source... Go to PubMed...
    17. Greenfield SP, Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. J. Urol. 1991; 146: 532-534. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.